Incannex Healthcare (IXHL) Stock Price, News & Analysis

Company Overview

Incannex Healthcare Limited is an Australia-based clinical-stage pharmaceutical company developing therapies for conditions with significant unmet medical needs. The company’s research programs focus on cannabinoid-based medicines and psychedelic-assisted psychotherapy, with development activities spanning sleep disorders, respiratory and inflammatory diseases, pain, and mental health.

Its pipeline includes IHL-42X, an investigational combination of dronabinol and acetazolamide being developed for obstructive sleep apnea. Incannex has also developed cannabinoid-based programs such as IHL-675A for inflammatory and fibrotic conditions, including idiopathic pulmonary fibrosis, and IHL-216A for traumatic brain injury and concussion. The company’s psychedelic medicine programs are designed to evaluate psilocybin-assisted psychotherapy for selected mental health conditions.

Incannex conducts clinical development and related research in Australia and the United States and has pursued regulatory pathways in both markets. The company is headquartered in Melbourne, Australia, and is led by Chief Executive Officer and Managing Director Joel Latham. Its shares trade on the Nasdaq Capital Market under the symbol IXHL and on the Australian Securities Exchange under the symbol IHL.

Key Stats

• Today's Range: $2.88 to $2.99
• 50-Day Range: $2.90 to $3.80
• 52-Week Range: $2.49 to $14.91
• Volume: 57,267 shs
• Average Volume: 95,024 shs
• Market Capitalization: $36.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Reduce

Incannex Healthcare Stock Analysis - MarketRank™

Incannex Healthcare scored higher than 58% of companies evaluated by MarketBeat, and ranked 418th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Incannex Healthcare has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 2 sell ratings.

Upside Potential

Incannex Healthcare has a consensus price target of $18.00, representing about 518.6% upside from its current price of $2.91.

Amount of Analyst Coverage

Incannex Healthcare has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Incannex Healthcare are expected to decrease in the coming year, from ($2.63) to ($2.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Incannex Healthcare is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incannex Healthcare is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Incannex Healthcare has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.68% of the float of Incannex Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Incannex Healthcare has a short interest ratio ("days to cover") of 3.88, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Incannex Healthcare has recently decreased by 36.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incannex Healthcare does not currently pay a dividend.

Dividend Growth

Incannex Healthcare does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.43

News Sentiment

Incannex Healthcare has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Incannex Healthcare this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for IXHL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

5 people have added Incannex Healthcare to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Incannex Healthcare insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.33% of the stock of Incannex Healthcare is held by insiders.

Percentage Held by Institutions

0.43% of the stock of Incannex Healthcare is held by institutions.

Company Calendar

• Last Earnings: 9/25/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:IXHL
• CIK: 1873875
• Web: www.incannex.com
• Phone: +61409840786
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Incannex Healthcare: $18.00
• High Price Target: $18.00
• Low Price Target: $18.00
• Potential Upside/Downside: +518.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -25.62%
• Return on Assets: -24.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 48.81
• Quick Ratio: 48.81

Sales & Book Value

• Annual Sales: $90 thousand
• Price / Sales: 405.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.63 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 12,550,000
• Free Float: 12,378,000
• Market Cap: $36.52 million
• Optionable: Not Optionable
• Beta: 6.97